Table 2.

Post-test probability of positive and negative BDG in non HIV critically ill patients with respiratory failure for the overall population and for the different subgroups of incidence

	General population	No ground glass	Ground glass and prophylaxis	Ground glass and no prophylaxis	Ground glass, no prophylaxis and lymphoid malignancy or HSCT
Incidence	4.1% [3.8–4.4]	2.0% [1.8–2.2]	4.8% [3.7–5.9]	10.0% [8.7–11.3]	20.3% [18.3–22.2]
			BDG+
Specific test	26.9% [25.3–28.9]	15.0% [13.7–16.3]	30.4% [25.0–35.0]	48.9% [45.1–52.3]	68.6% [65.8–71.1]
Intermediate	22.9% [21.5–24.3]	12.5% [11.4–13.6]	26.0% [21.2–30.3]	43.6% [39.9–47.0]	63.9% [60.8–66.5]
Sensitive test	18.9% [17.6–20.0]	10.0% [9.1–10.9]	21.5% [17.4–25.3]	37.6% [34.1–40.9]	58.0% [54.9–60.8]
			BDG -
Specific test	0.41% [0.38–0.45]	0.20% [0.18–0.22]	0.49% [0.37–0.60]	1.06% [0.91–1.23]	2.40% [2.12–2.71]
Intermediate	0.23% [0.21–0.25]	0.11% [0.10–0.12]	0.27% [0.21–0.34]	0.60% [0.51–0.69]	1.36% [1.19–1.54]
Sensitive test	0.18% [0.16–0.19]	0.08% [0.07–0.09]	0.21% [0.16–0.26]	0.45% [0.39–0.53]	1.03% [0.90–1.18]